Recent News

• 04.23.2025 - Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025
• 04.23.2025 - Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025
• 04.17.2025 - Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
• 04.17.2025 - Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
• 04.09.2025 - Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
• 04.09.2025 - Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
• 03.26.2025 - Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value
• 03.26.2025 - Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value
• 03.21.2025 - Atea Pharmaceuticals Issues Statement Regarding Director Nominations

Recent Filings

• 04.17.2025 - 8-K Current report
• 04.17.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 04.17.2025 - EX-99.1 EX-99.1
• 04.03.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.01.2025 - 8-K Current report
• 04.01.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 03.26.2025 - DFAN14A Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material
• 03.26.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 03.24.2025 - 8-K Current report
• 03.24.2025 - EX-99.1 EX-99.1